Evaluation of 7 nicotinic acetylcholine receptor agonists and positive allosteric modulators using the parallel oocyte electrophysiology test station

Assay and Drug Development Technologies

Volumn 7, Issue 4, 2009, Pages 374-390

  Malysz, John ^a   Grønlien, Jens H ^b   Timmermann, Daniel B ^c   Håkerud, Monika ^b   Thorin Hagene, Kirsten ^b   Ween, Hilde ^b   Trumbull, Jonathan D ^a   Xiong, Yongli ^a   Briggs, Clark A ^a   Ahring, Philip K ^c   Dyhring, Tino ^c   Gopalakrishnan, Murali ^a  

^a ABBOTT LABORATORIES   (United States)

^b Research and Development   (Norway)

^c NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; 5 HYDROXYINDOLE; A 582941; A 746050; A 795723; A 844606; ACETYLCHOLINE; ACETYLCHOLINE RECEPTOR ALPHA7; CALCIUM ION; CHOLINE; CHOLINERGIC RECEPTOR; GENISTEIN; NICOTINE; NICOTINIC AGENT; NS 1738; NS 6784; TILORONE; UNCLASSIFIED DRUG; VARENICLINE; 1 (5 CHLORO 2,4 DIMETHOXYPHENYL) 3 (5 METHYLISOXAZOL 3 YL)UREA; 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-METHYLISOXAZOL-3-YL)UREA; 3-(2,4-DIMETHOXYBENZYLIDENE)ANABASEINE; ALPHA-BUNGAROTOXIN RECEPTOR; BENZYLIDENE DERIVATIVE; BUNGAROTOXIN RECEPTOR; CARBANILAMIDE DERIVATIVE; ISOXAZOLE DERIVATIVE; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ELECTROPHYSIOLOGY; EVOKED RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; OOCYTE; PATCH CLAMP; SIGNAL TRANSDUCTION; VOLTAGE CLAMP; ANIMAL; DOSE RESPONSE; DRUG DEVELOPMENT; NEUROBLASTOMA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOPUS LAEVIS;

ANIMALS; BENZYLIDENE COMPOUNDS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; ELECTROPHYSIOLOGY; FEMALE; HUMANS; ISOXAZOLES; NEUROBLASTOMA; NICOTINIC AGONISTS; OOCYTES; PATCH-CLAMP TECHNIQUES; PHENYLUREA COMPOUNDS; PYRIDINES; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 70350098353     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0194     Document Type: Article

References (56)

1. Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, et al.: Broad-spectrum effi cacy across cognitive domains by alpha7 nicotinic acetyl- choline receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 2007;27:10578-10587.
2. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, et al.: SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) effi cacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007;32:17-34.
3. Hajos M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, et al.: The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)- 1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating defi cits in anesthetized rats. J Pharmacol Exp Ther 2005;312:1213-1222.
4. Levin ED, Bettegowda C, Blosser J, Gordon J: AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 1999;10:675-680.
5. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, et al.: A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 2005;25: 4396-4405.
6. Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, et al.: Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A 2007;104:8059-8064.
7. Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EO, Dam E, Jorgensen TD, et al.: An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 2007;323:294-307.
8. Hansen HH, Timmermann DB, Peters D, Walters C, Damaj MI, Mikkelsen JD: Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. J Neurosci Res 2007;85:1810-1818.
9. Memory Pharmaceuticals announces positive Phase 2a results for MEM 3454 in Alzheimer's Disease. http://www.oxbio.com/pressreleases/110207-Memory. pdf (accessed May 1, 2009).
10. Anderson DJ, Bunnelle WH, Surber BW, Du J, Surowy CS, Tribollet E, et al.: [3H] A-585539, a novel high affi nity á7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain. J Pharmacol Exp Ther 2008;324:179-187.
11. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, et al.: SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007;32:1-16.
12. Walker DP, Wishka DG, Piotrowski DW, Jia S, Reitz SC, Yates KM, et al.: Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem 2006;14:8219-8248.
13. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, et al.: Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5- carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive defi cits in schizophrenia: synthesis and structure-activity relationship. J Med Chem 2006;49:4425-4436.
14. Feuerbach D, Nozulak J, Lingenhoehl K, McAllister K, Hoyer D: JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist. Neurosci Lett 2007;416:61-65.
15. Deuther-Conrad W, Patt JT, Feuerbach D, Wegner F, Brust P, Steinbach J: Norchloro-fl uoro-homoepibatidine: specifi city to neuronal nicotinic acetylcholine receptor subtypes in vitro. Farmaco 2004;59:785-792.
16. Wonnacott S, Barik J: Nicotinic ACh receptors. Tocris Bioscience Scientifi c Review Series 2007. http://www.tocris.com/pdfs/pdf-downloads/ receptor- binding-review.pdf (accessed Jul 29, 2009).
17. Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajos M, et al.: Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J Med Chem 2005;48:905-908.
18. Christensen JK, Loechel F, Jorgensen S, Ahring PK, Jensen ML, Timmermann DB, et al.: Establishment of HTS assays for measurement of positive allosteric modulators of nicotinic á7 receptors [abstract]. Biochem Pharmacol 2007;74(8):SMA-15.
19. Grønlien JH, Cassar S, Thorin-Hagene K, Ween H, Li J, Bertrand S, et al.: Positive allosteric modulation of á7 nAChR by genistein and 5-HI involves distinct sites: evidence from á7-5-HT3A chimera studies [abstract]. Biochem Pharmacol 2007;74(8):SMA-13-SMA-14.
20. Feuerbach D, Lingenhohl K, Dobbins P, Mosbacher J, Corbett N, Nozulak J, et al.: Coupling of human nicotinic acetylcholine receptors alpha 7 to calcium channels in GH3 cells. Neuropharmacology 2005;48:215-227.
21. Quik M, Philie J, Choremis J: Modulation of alpha7 nicotinic receptor-mediated calcium infl ux by nicotinic agonists. Mol Pharmacol 1997;51:499-506.
22. Grønlien JH, Hakerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, et al.: Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 2007;72:715-724.
23. Dunlop J, Roncarati R, Jow B, Bothmann H, Lock T, Kowal D, et al.: In vitro screening strategies for nicotinic receptor ligands. Biochem Pharmacol 2007;74:1172-1181.
24. Briggs CA, Schrimpf MR, Anderson DJ, Gubbins EJ, Grønlien JH, Hakerud M, et al.: alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues. Br J Pharmacol 2008;153:1054-1061.
25. Lopez-Hernandez G, Placzek AN, Thinschmidt JS, Lestage P, Trocme-Thibierge C, Morain P, et al.: Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology 2007;53:134-144.
26. Friis S, Mathes C, Sunesen M, Bowlby MR, Dunlop J: Characterization of compounds on nicotinic acetylcholine receptor alpha7 channels using higher throughput electrophysiology. J Neurosci Methods. 2009;177:142-148.
27. Friis S, Mathes C, Sunesen M, Bowlby MR, Dunlop J: Characterization of compounds on nicotinic acetylcholine receptor alpha7 channels using higher throughput electrophysiology. J Neurosci Methods 2009;177:142-148.
28. OpusXpress 6000A. Automated parallel voltage-clamp screening system for oocytes. http://www.moleculardevices.com/pages/instruments/opusxpress. html (accessed May 1, 2009).
29. Trumbull JD, Maslana ES, McKenna DG, Nemcek TA, Niforatos W, Pan JY, et al.: High throughput electrophysiology using a fully automated, multiplexed recording system. Receptors Channels 2003;9:19-28.
30. Shieh CC, Trumbull JD, Sarthy JF, McKenna DG, Parihar AS, Zhang XF, et al.: Automated Parallel Oocyte Electrophysiology Test station (POETs): a screening platform for identifi cation of ligand-gated ion channel modulators. Assay Drug Dev Technol 2003;1:655-663.
31. Papke RL, Porter Papke JK: Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis. Br J Pharmacol 2002;137: 49-61.
32. Papke RL, Smith-Maxwell C: High throughput electrophysiology with Xenopus oocytes. Comb Chem High Throughput Screen 2009;12:38-50.
33. Briggs CA, McKenna DG: Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 1998;37:1095-1102.
34. Briggs CA, McKenna DG, Piattoni-Kaplan M: Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 1995;34:583-590.
35. Gopalakrishnan SM, Philip BM, Anderson DJ, Malysz J, Burns DJ, Gopalakrishnan M, et al.: Functional characterization of positive allosteric modulators of á7 nicotinic acetylcholine receptors in IMR-32 neuroblastoma cells. Presented at the 14th Annual Conference of Society for Biomolecular Sciences, 2008. http://www.conferencearchives.com/sbs/2008/ abstracts/P15006-a.php (accessed Jul 29, 2009).
36. Faghih R, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, Ween H, Curtis MP, Sarris KA, Gfesser GA, El-Kouhen R, Robb HM, Radek RJ, Marsh KC, Bunnelle WH, Gopalakrishnan M: Discovery of 4-(5-(4-chlorophenyl)- 2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. J Med Chem 2009;52:3377-3384.
37. Briggs CA, Grønlien JH, Timmermann DB, Kerr P, Curzon P, Damsgaard J, et al.: Role of channel activation in á7 nAChR-mediated congitive enhancement [abstract]. Biochem Pharmacol 2007;74(8):SMA-25-SMA-26.
38. Khiroug SS, Harkness PC, Lamb PW, Sudweeks SN, Khiroug L, Millar NS, et al.: Rat nicotinic ACh receptor alpha7 and beta2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol 2002;540:425-434.
39. Papke RL: Estimation of both the potency and effi cacy of alpha7 nAChR agonists from single-concentration responses. Life Sci 2006;78:2812-2819.
40. Meyer EM, Kuryatov A, Gerzanich V, Lindstrom J, Papke RL: Analysis of 3-(4-hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors. J Pharmacol Exp Ther 1998;287:918-925.
41. Redrobe JP, Nielsen EO, Christensen JK, Peters D, Timmermann DB, Olsen GM: Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamineinduced behavioural changes in a modifi ed continuous Y-maze task in mice. Eur J Pharmacol 2009;602:58-65.
42. Mihalak KB, Carroll FI, Luetje CW: Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006;70:801-805.
43. Zwart R, De Filippi G, Broad LM, McPhie GI, Pearson KH, Baldwinson T, et al.: 5-Hydroxyindole potentiates human alpha 7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 2002;43:374-384.
44. Cho CH, Song W, Leitzell K, Teo E, Meleth AD, Quick MW, et al.: Rapid upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J Neurosci 2005;25:3712-3723.
45. Charpantier E, Wiesner A, Huh KH, Ogier R, Hoda JC, Allaman G, et al.: Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J Neurosci 2005;25:9836-9849.
46. Malysz J, Grønlien JH, Anderson DJ, Håkerud M, Thorin-Hagene K, Ween H, Wetterstrand C, Briggs CA, Faghih R, Bunnelle WH, Gopalakrishnan M: In vitro pharmacological characterization of a novel allosteric modulator of alpha7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3- propionyl- 1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther 2009;330:257-267.
47. Simosky JK, Stevens KE, Kem WR, Freedman R: Intragastric DMXB-A, an alpha7 nicotinic agonist, improves defi cient sensory inhibition in DBA/2 mice. Biol Psychiatry 2001;50:493-500.
48. Stevens KE, Kem WR, Mahnir VM, Freedman R: Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 1998;136:320-327.
49. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR: Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 1995;674:252-259.
50. Woodruff-Pak DS, Li YT, Kem WR: A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res 1994;645:309-317.
51. Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, et al.: Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 1997;57:231-241.
52. Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP, et al.: Sazetidine- A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 2006;70:1454-1460.
53. Zwart R, Carbone AL, Moroni M, Bermudez I, Mogg AJ, Folly EA, et al.: Sazetidine- A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Mol Pharmacol 2008;73:1838-1843.
54. Buccafusco JJ, Beach JW, Terry AV Jr: Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 2009;328:364-370.
55. Bertrand D, Gopalakrishnan M: Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 2007;74:1155-1163.
56. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, et al.: Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53:283-294.